Financial Performance - The company's operating revenue for Q1 2025 was ¥2,730,189,121.97, a decrease of 14.63% compared to ¥3,198,046,619.86 in the same period last year[5] - Net profit attributable to shareholders was ¥248,547,145.11, representing a slight increase of 1.98% from ¥243,716,289.99 year-on-year[5] - The basic and diluted earnings per share were both ¥0.2126, reflecting a growth of 2.02% from ¥0.2084 in the same period last year[5] - Net profit increased to ¥248,576,261.58 compared to ¥243,714,001.08, showing a growth of approximately 2.3%[18] - The total profit margin for the period was approximately 10.9%, slightly down from the previous margin of 11.1%[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥14,993,469.16, a decline of 105.35% compared to ¥280,125,473.87 in the previous year[5] - Operating cash flow generated a net outflow of ¥14,993,469.16, contrasting with a net inflow of ¥280,125,473.87 in the previous period[19] - Cash and cash equivalents decreased to CNY 3,465,233,609.71 from CNY 3,661,618,802.74, reflecting a decline of approximately 5.36%[14] - Cash and cash equivalents at the end of the period stood at ¥2,594,930,339.41, slightly down from ¥2,599,072,264.47[20] - Investment activities resulted in a net cash outflow of ¥91,370,688.15, compared to a larger outflow of ¥188,142,141.05 in the prior period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,708,540,956.72, a slight decrease of 0.16% from ¥12,729,008,610.16 at the end of the previous year[5] - Current assets totaled CNY 8,228,646,015.77, compared to CNY 8,186,761,774.66 at the start of the period, indicating a growth in liquidity[14] - Total liabilities decreased to CNY 5,709,989,761.76 from CNY 5,979,125,430.44, indicating a reduction of about 4.49%[15] - The company's equity attributable to shareholders increased to CNY 6,990,603,683.93 from CNY 6,741,964,785.16, reflecting an increase of approximately 3.69%[16] - Short-term borrowings decreased to CNY 668,156,422.52 from CNY 814,026,241.34, a reduction of about 17.94%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,719, with the largest shareholder holding 28.30% of the shares[10] - The company repurchased 10,880,000 shares, representing 0.93% of the total share capital[11] Investment and Other Income - The company reported a significant increase in investment income to ¥39,456,689.06, compared to a loss of -¥2,018,356.21 in the previous year[9] - Non-recurring gains and losses totaled ¥42,881,422.13, primarily from the disposal of non-current assets and government subsidies[6] Research and Development - Research and development expenses increased to ¥169,688,023.08 from ¥152,938,500.76, reflecting a rise of about 11%[17] Other Financial Metrics - The company's return on equity (ROE) was 4.00%, an increase of 0.16% compared to 3.84% from the previous year[5] - Accounts receivable financing increased by 195.96% to ¥539,323,041.79, mainly due to an increase in received bills[9] - Accounts receivable increased to CNY 1,832,342,320.15 from CNY 1,764,198,282.30, representing a growth of about 3.86%[14] - Inventory decreased to CNY 1,651,614,838.63 from CNY 1,860,088,103.67, showing a decline of approximately 11.21%[14] - The company reported a significant increase in long-term receivables, rising to CNY 3,888,628.75 from CNY 3,483,230.30, an increase of approximately 11.63%[15] - The company experienced a foreign exchange impact of ¥3,246,242.93 on cash and cash equivalents[20]

Group 1 - The core point of the article is that Prologis Pharmaceutical (000739) reported a decline in revenue for the first quarter of 2025, while net profit showed a slight increase [1] - The company's operating revenue for Q1 2025 was 2.73 billion yuan, representing a year-on-year decrease of 14.63% [1] - The net profit for the same period was 249 million yuan, which reflects a year-on-year growth of 1.98% [1]

北京市朝阳区建外大街丁 12 号英皇集团中心 8 层 8/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 北京市康达律师事务所 关于普洛药业股份有限公司 2024 年年度股东大会的法律意见书 康达股会字【2025】第 0083 号 致：普洛药业股份有限公司 北京市康达律师事务所（以下简称"本所"）接受普洛药业股份有限公司（以 下简称"公司"）的委托，指派本所律师参加公司 2024 年年度股东大会（以下简 称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000739 证券简称：普洛药业 公告编号：2025-23 普洛药业股份有限公司 2024 年年度股东大会决议公告 特别提示： 1、本次股东大会未有否决议案。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 3、根据国家有关法律、法规等相关规定，上市公司回购专用证券账户所持 股份不享有股东大会的表决权，公司现有总股本1,169,323,576股，截至本次股 东大会股权登记日，公司回购专用证券账户持有公司股份10,880,000股，故公司 本次股东大会有表决权股份总数为1,158,443,576股。 1、召集人：公司第九届董事会 2、主持人：公司董事长 祝方猛先生 3、会议召开方式：现场投票与网络投票相结合 4、会议召开时间： （1）现场会议召开时间：2025 年 4 月 17 日下午 14:30 （2）网络投票时间：2025 年 4 月 17 日 一、会议召开和出席情况 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 4 月 17 日：9:15—9:25，9:30—11:3 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

Summary of Conference Call Company Overview - The conference call was hosted by a pharmaceutical company, 普利奥运 (Puliouyun), discussing its operational performance for 2024 and future outlooks [1] Key Financial Metrics - Revenue for 2024 reached 12.022 billion, a year-on-year increase of 4.77% [2] - Gross profit was 1.031 billion, a decrease of 2.29% year-on-year [2] - Revenue from the fuel segment was 8.651 billion, up 8.32% year-on-year, but gross margin decreased by 7.68% [2] - The CDMO segment reported revenue of 1.884 billion, down 6.05% year-on-year [2] R&D and Investment - R&D investment for the year was 611 million, a 2.66% increase year-on-year, with expectations for continued growth in R&D spending [3] - The company has 355 commercialized projects, a 25% increase year-on-year, with 262 in usable drugs and 48 in social drugs [4] - The company has signed confidentiality agreements with 572 innovative drug companies, increasing by over 100 projects from the previous year [4] CDMO Business Insights - The CDMO business is seen as a major growth driver, with ongoing collaborations with both domestic and international companies [10] - The company aims to increase its API projects significantly, projecting 10 to 15 new DMFs annually over the next three years [5] - The CDMO team is expected to grow from 600 to around 1,000 personnel in the next two years [14] Market Challenges and Strategies - The pharmaceutical industry is experiencing intense competition, particularly in the antibiotic sector, leading to price pressures [15] - The company anticipates continued challenges in 2025 due to domestic market competition and geopolitical uncertainties [8] - Strategies include enhancing operational efficiency and adjusting production methods to mitigate price declines [15] Future Outlook - The company expects moderate growth in the CDMO segment, with a target of 3,000 operational projects in two years [18] - Gross margin is projected to increase slightly, with expectations of a 1-2% growth from the previous year's 41% [22] - The company emphasizes the importance of long-term investment strategies and technological innovation for sustainable growth [40] Additional Insights - The company is focusing on the medical beauty segment, which is expected to grow significantly, although its current contribution is limited [27] - The impact of price reductions due to competitive bidding is anticipated to be manageable, with a predicted effect of no more than 10% on overall performance [37] - The company is committed to maintaining a stable growth rate of around 20% over the coming years through strategic investments and operational improvements [31]

智通财经4月11日电，普洛药业在互动平台表示，公司2024年度直接出口美国的产品收入大约为5000万 美元，约占公司总出口收入的7%左右。目前，公司对美国的业务主要是CDMO和API业务，药品（制 剂）业务尚处于拓展期，销售很少，因此美国对药品加征关税，目前对公司影响较小。 普洛药业：对美出口收入约占公司总出口收入7% 美对药品加征关税影响较小 ...

Core Viewpoint - Prolo Pharmaceutical Co., Ltd. is currently engaged in a share repurchase plan aimed at implementing employee stock ownership and incentive programs, with a maximum repurchase price set at 22 RMB per share and a total repurchase fund between 75 million and 150 million RMB [2][4]. Trading Information Summary - As of April 2, 2025, Prolo Pharmaceutical's stock closed at 15.29 RMB, down 0.91%, with a turnover rate of 0.75%, a trading volume of 88,000 shares, and a transaction amount of 135 million RMB [1]. - On the same day, the main funds experienced a net outflow of 18.1 million RMB, accounting for 13.4% of the total transaction amount [2][4]. - Retail investors saw a net inflow of 19.1 million RMB, representing 14.11% of the total transaction amount [2]. Company Announcement Summary - The company announced on February 19, 2025, that it would use its own funds to repurchase shares through centralized bidding, with the repurchase period set for 12 months from the board's approval date [2]. - As of March 31, 2025, Prolo Pharmaceutical had not yet executed any share repurchases through the designated securities account [2][4].

证券代码：000739 证券简称：普洛药业 公告编号：2025-22 普洛药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开第九届 董事会第十次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司股权激励和员工 持股计划。本次回购股份价格不超过人民币22元/股（含），回购资金总额不低 于人民币7,500万元（含）且不超过人民币15,000万元（含）。具体回购股份数 量以回购期限届满或回购股份实施完毕时实际回购股份数量为准。回购期限为自 公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于 2025 年 2 月 20 日 、 2025 年 2 月 21 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十次会议决议公告》 （公告编号：2025-04）、《关于回购公司股份方案的公告》（公告编号：2025-05） 及《关于回 ...